Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma.

Soon Kyu LeePil-Soo Sung Sung Soo ParkChang-Ki MinHeechul NamJeong Won JangJong Young ChoiSeung Kew Yoon

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.

Keyphrases

multiple myeloma
hepatitis b virus
liver failure
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
smoking cessation